Resverlogix Corp. | Income Statement

Fiscal year is May-April. All values CAD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
156.90
243.60
373.70
496.70
457.60
Gross Income
156.90
243.60
373.70
496.70
457.60
SG&A Expense
14,211.50
9,499.20
26,019.20
44,575.10
52,792.30
EBIT
14,368.40
9,742.80
26,392.90
45,071.80
53,249.90
Unusual Expense
74,681.50
8,602.90
7,686.50
10,262.80
9,392.20
Non Operating Income/Expense
2,095.60
2,706.00
856.70
3,742.80
4,987.50
Interest Expense
3,931.60
6,692.10
8,144.50
9,266.80
6,967.50
Pretax Income
58,477.20
22,331.70
25,994.20
60,858.50
74,597.10
Income Tax
66.80
1,277.70
50.00
19.80
65.20
Consolidated Net Income
58,410.40
21,054.00
25,944.20
60,878.30
74,531.90
Net Income
58,410.40
21,054.00
25,944.20
60,878.30
74,531.90
Net Income After Extraordinaries
58,410.40
21,054.00
25,944.20
60,878.30
74,531.90
Net Income Available to Common
58,410.40
21,054.00
25,944.20
60,878.30
74,531.90
EPS (Basic)
0.73
0.25
0.26
0.58
0.54
Basic Shares Outstanding
79,495.50
85,076.80
100,975.70
105,352.80
137,737.60
EPS (Diluted)
0.73
0.25
0.26
0.58
0.54
Diluted Shares Outstanding
80,430.70
85,076.80
100,975.70
105,352.80
137,737.60
EBITDA
14,211.50
9,499.20
26,019.20
44,575.10
52,792.30

About Resverlogix

View Profile
Address
4820 Richard Road SW
Calgary Alberta T3E 6L1
Canada
Employees -
Website http://www.resverlogix.com
Updated 07/08/2019
Resverlogix Corp. is a clinical stage biotechnology company, which engages in the research and development of pharmaceutical products for cardiovascular diseases. It develops Apabetalone for diabetes mellitus, chronic kidney, peripheral artery, Orphan and Alzheimer's diseases. The company was founded by Donald J.